What is Holoclara?
Holoclara is a pioneering biotechnology enterprise dedicated to the development of orally available, worm-derived therapies. Founded by physician-scientist Andrea Choe, the company utilizes proprietary methods to mine potent immunomodulatory molecules from gut roundworms. This scientific strategy is rooted in extensive preclinical data demonstrating the efficacy of these molecules in modulating the human immune system to combat autoimmune and allergic diseases. By bridging the gap between evolutionary biology and modern pharmacology, Holoclara aims to provide relief to millions of patients suffering from conditions that have historically remained untreatable through conventional pharmaceutical interventions.
How much funding has Holoclara raised?
Holoclara has raised a total of $16M across 1 funding round:
Series A
$16M
Series A (2024): $16M with participation from BOLD Capital Partners, FreeFlow Ventures, and Horizons Ventures
Key Investors in Holoclara
BOLD Capital Partners
BOLD Capital Partners is a venture capital firm dedicated to investing in entrepreneurs and technologies that aim to transform the world by identifying emerging science that can disrupt large markets.
FreeFlow Ventures
FreeFlow Ventures is a venture builder and studio focused on providing investment facilitation and technology development support to startups ranging from early to growth stages.
Horizons Ventures
Horizons Ventures focuses on investing in deep science and technology aimed at advancing humanity towards a significantly improved future through transformative innovation.
What's next for Holoclara?
With the recent capital injection, Holoclara is poised to scale its research and development operations significantly. The strategic roadmap involves advancing its lead candidates through rigorous clinical trials while expanding its intellectual property portfolio surrounding worm-derived therapeutics. As the company moves deeper into the clinical phase, the focus will shift toward establishing regulatory pathways and scaling manufacturing processes for its novel oral therapies. This growth trajectory positions Holoclara to potentially disrupt the autoimmune market, offering a new class of biological agents that could redefine standard-of-care protocols for chronic inflammatory disorders.
See full Holoclara company page
